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The N-terminal 17 amino acids of huntingtin (NT17)
can be phosphorylated on serines 13 and 16;
however, the significance of these modifications in
Huntington’s disease pathogenesis remains
unknown. In this study, we developed BAC trans-
genic mice expressing full-length mutant huntingtin
(fl-mhtt) with serines 13 and 16 mutated to either
aspartate (phosphomimetic or SD) or alanine (phos-
phoresistant or SA). Both mutant proteins preserve
the essential function of huntingtin in rescuing
knockout mouse phenotypes. However, fl-mhtt-
induced disease pathogenesis, including motor and
psychiatric-like behavioral deficits, mhtt aggrega-
tion, and selective neurodegeneration are abolished
in SD but preserved in SA mice. Moreover, modifica-
tion of these serines in expanded repeat huntingtin
peptides modulates aggregation and amyloid fibril
formation in vitro. Together, our findingsdemonstrate
that serines 13 and 16 are critical determinants of
fl-mhtt-induced disease pathogenesis in vivo, sup-
porting the targeting of huntingtin NT17 domain and
its modifications in HD therapy.
INTRODUCTION
Huntington’s disease (HD) is an autosomal-dominant and
progressive neurodegenerative disorder characterized by move-
ment disorders, cognitive impairment, and psychiatric symp-828 Neuron 64, 828–840, December 24, 2009 ª2009 Elsevier Inc.toms (Harper, 1996). HD is caused by a polyglutamine (polyQ)
repeat expansion near the N terminus of huntingtin (Htt), a very
large 350 kDa protein (The Huntington’s Disease Collaborative
Research Group, 1993). Huntingtin is thought to function as
a scaffolding protein that mediates a variety of protein-protein
interactions involved in vesicular trafficking, signaling, and tran-
scription (MacDonald, 2003; Li and Li, 2006). HD neuropathology
is characterized by the selective loss of predominantly medium-
sized spiny neurons (MSNs) in the striatum and to a lesser extent
the pyramidal neurons in the deep layers of the cortex (Vonsattel
and DiFiglia, 1998). Another pathological hallmark of HD is the
accumulation of nuclear and cytoplasmic protein aggregates
containing mhtt N-terminal polyQ fragments in the cortex and
striatum (DiFiglia et al., 1997; Gutekunst et al., 1999). Currently,
it remains unclear how mhtt can cause progressive neuronal
dysfunction and selective neurodegeneration in the brain (Orr
and Zoghbi, 2007; Li and Li, 2006). Unraveling the underlying
pathogenic mechanisms may provide important clues to the
development of effective treatments for this lethal neurodegen-
erative disorder.
Although protein misfolding due to polyQ expansion appears
to be a shared pathogenic mechanism in all polyQ disorders
(Orr and Zoghbi, 2007; Williams and Paulson, 2008; Bates,
2003; Ross and Poirier, 2004), the critical molecular pathway
through which misfolded polyQ proteins elicit disease-specific
clinical and pathological outcomes remain unresolved. Recent
studies reveal a critical role for the specific protein context
beyond the expanded polyQ domain in modifying disease path-
ogenesis (Gatchel and Zoghbi, 2005; Orr and Zoghbi, 2007;
Katsuno et al., 2002). In HD, covalent posttranslational modifica-
tions of mhtt have been implicated in disease pathogenesis
(Schilling et al., 2006; Steffan et al., 2004; Jeong et al., 2009;
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However, in all but one case (i.e., the caspase-6 cleavage site;
Graham et al., 2006), the pathogenic significance of htt cis-
domain modifications in vivo has been assessed using mhtt
N-terminal fragment models. Therefore, it remains to be ad-
dressed how these modifications may influence disease patho-
genesis in the context of fl-mhtt in a mammalian model of HD.
Emerging data suggest that the N-terminal 1–17 amino acids
of htt (NT17 domain) immediately preceding the polyQ domain
may constitute a critical functional domain for htt function and
HD pathogenesis (Steffan et al., 2004; Cornett et al., 2005; Rock-
abrand et al., 2007; Atwal et al., 2007; Aiken et al., 2009). The
NT17 domain is highly conserved evolutionarily and can mediate
htt binding to peripheral membranous structures (Atwal et al.,
2007; Rockabrand et al., 2007). The NT17 domain can function
as a cytoplasmic retention signal and deletions or certain point
mutations in this domain result in nuclear accumulation of htt in
cultured cells (Rockabrand et al., 2007; Cornett et al., 2005;
Steffan et al., 2004; Atwal et al., 2007). The NT17 domain can
also be covalently modified by ubiquitylation and SUMOylation,
which appear to have opposing effects on the toxicity of mhtt
fragments in a transgenic Drosophila model (Steffan et al.,
2004). Recent biochemical analyses reveal that interaction of
the NT17 domain with the adjacent polyQ domain can accelerate
mhtt exon 1 peptide aggregation via a novel and complex
pathway (Thakur et al., 2009). This converging evidence
suggests that the NT17 domain and its modifications may play
important roles in the physical and biological properties of
wild-type htt, and in the toxicity of fl-mhtt and its toxic fragments.
In neurodegenerative diseases, phosphorylation of disease
proteins such as tau (Ballatore et al., 2007), SCA1 (Emamian
et al., 2003), and a-synuclein (Fujiwara et al., 2002) has been
shown to play important roles in disease pathogenesis. Recent
studies reveal that serines 13 and 16 (S13 and S16) in htt NT17
domain can be phosphorylated in cultured mammalian cells
(Aiken et al., 2009; Thompson et al., 2009). To address the impor-
tance of these modifications in disease pathogenesis elicited by
fl-mhtt in a mammalian model of HD, we have introduced either
phosphomimetic (SD) or phosphoresistant (SA) mutations into
fl-mhtt. Dramatically, SD but not SA fl-mhtt can prevent progres-
sive neuronal dysfunction, mhtt aggregation, and late-onset
neurodegenerative pathology in vivo. Moreover, an in vitro
aggregation assay reveals that the SD mutations significantly
compromise the fibrillization of mhtt-exon 1 peptides, whereas
SA mutations do not. Thus, we provide strong evidence that
S13 and S16 in htt NT17 domain play a critical role in modulating
polyQ-induced misfolding and/or aggregation in vitro and
fl-mhtt-induced disease pathogenesis in vivo.
RESULTS
Generation and Biochemical Characterization of BAC
Transgenic Mice with Mutations at S13 and S16
of Full-Length Mutant Huntingtin
To evaluate the pathogenic relevance of S13 and S16 phosphor-
ylation in mammalian models of HD, we re-engineered the S13
and S16 residues of our previous BACHD construct (fl-mhtt-
[97Q]; Gray et al., 2008) to aspartate (SD), a mutation commonlyused to mimic serine phosphorylation. We also mutated the two
serine residues to alanine (SA), which renders the mhtt NT17
domain incapable of being phosphorylated at these sites
(Figure 1A). The structural integrity of the engineered SD and
SA BACs were confirmed with pulse field gel electrophoresis
(Figure S1A) and the purified DNA was microinjected into FvB/N
one-cell embryos to generate transgenic founders (Figures S1B
and S1C). Five founders for the BACHD-SD construct and two
founders for the BACHD-SA mutant were obtained, and initial
expression analyses of the F1 mice from these lines identified
two lines with SD mutations (lines B and C) and one line with SA
mutations expressing fl-mhtt protein at suitable levels (see
below). The mutant htt exon 1 region was PCR amplified and
sequenced to confirm the appropriate mutations at S13 and
S16, and a polyQ repeat length of 97 (Figures S1D and S1E;
Table 1). These mouse lines were expanded by breeding with
FvB/NJ wild-type mice, the same inbred mouse background
used in the previous phenotypic characterization of BACHD
mice (Gray et al., 2008; Spampanato et al., 2008; Menalled
et al., 2009).
We next used S13- and S16-phosphospecific htt antibodies to
confirm the specificity of the S13 and S16 mutations at the
protein level in SD and SA mice. The binding of these antibodies
should be prevented following either SD or SA mutation in
fl-mhtt, and only unmodified, phosphorylated htt will be recog-
nized by phosphospecific antibodies. Consistent with this
prediction, we were able to immunoprecipitate fl-mhtt from
BACHD brains using S13- and S16-phosphospecific htt anti-
bodies, but not the NT17-mutated fl-mhtt from SD and SA brains
(Figure S2). Thus, we were able to show that the phosphorylated
species of fl-mhtt can be detected in BACHD brains and confirm
the molecular specificity of the S13 and S16 mutations in the
context of fl-mhtt-[97Q] protein isolated from SD and SA brains.
We next assessed the fl-mhtt-[97Q] protein levels in BACHD,
BACHD-L, BACHD-SD, and BACHD-SA mice. BACHD-L mice
express fl-mhtt-[97Q] at about one-third the level of the BACHD
mice but still demonstrate evidence of disease pathogenesis
(Gray et al., 2008; Table 1). We performed quantitative western
blot analysis to ensure that fl-mhtt-[97Q] protein levels in SD
and SA mice were at or above the fl-mhtt-[97Q] level in
BACHD-L mice and therefore would be expected to elicit at least
some disease pathogenesis. We quantified the relative expres-
sion of fl-mhtt-[97Q] using two anti-polyQ monoclonal anti-
bodies: 1C2 (Figure 1B) and 4H7H7 (Figure S3A). The mouse
monoclonal 4H7H7 antibody can recognize mhtt N-terminal
fragment (1–480 amino acid) with 68Q but not the same htt frag-
ment with 17Q (Figure S3B). 4H7H7 can also recognize on
western blots two other expanded polyQ proteins, mutant
ataxin-1 and ataxin-3, but not their corresponding wild-type
proteins with nonpathogenic polyQ repeats (Figures S3C and
S3D). In our series of BACHD models, both 4H7H7 and 1C2
can specifically recognize human mhtt but not endogenous
murine wild-type htt (Figures 1B and S3A). Since these different
BACHD mouse lines all have the same length polyQ repeat,
western blot quantification of fl-mhtt with the anti-polyQ anti-
body 1C2 can accurately determine the relative expression level
of soluble, steady-state fl-mhtt (Figure 1C and Table 1). We
determined the relative levels of fl-mhtt-[97Q] in brain extractsNeuron 64, 828–840, December 24, 2009 ª2009 Elsevier Inc. 829
Figure 1. Generation and Biochemical
Characterization of the Phosphomimetic
(SD) and Phosphoresistant (SA) BACHD
Transgenic Mice
(A) A schematic representation of the S13,16A and
S13,16D mutations within the NT17 domain in the
BACHD construct (Gray et al., 2008).
(B) A representative western blot of cortical protein
extracts made from 1-month-old BACHD,
BACHD-L, SA, SD-B, SD-C, and SD-C heterozy-
gous (het) mice. The blot was probed with
polyQ-specific 1C2 antibody followed by anti-
tubulin antibody for loading controls.
(C) Quantification of the fl-mhtt expression levels in
various HD transgenic mouse lines. Densitometry
values of individual bands are based on three
1C2 western blots using independent cortical
extracts. The input in each lane is normalized using
the anti-a-tubulin control. The results of three inde-
pendent experiments are expressed as means ±
SEM. One-way ANOVA analysis reveals that there
are significant differences between the fl-mhtt
expression levels in BACHD, BACHD-L, SA, SD-
C, SD-B, and SD-C (het) mice (F(4,11) = 22.090,
p < 0.001). The post hoc test (LSD) indicates that
the BACHD-L fl-mhtt expression level is signifi-
cantly lower than the fl-mhtt expression level in
the BACHD (p < 0.001), SA (p = 0.001), SD-C (p =
0.017), and SD-B (p = 0.01) mice, but does not
differ from the SD-C (het) mice (p = 0.34).
Error bars indicate mean ± SEM.
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SD-B line homozygotes, and SD-C line homozygotes and
heterozygotes [SD-C (het)] (n = 3 per genotype). Using one-
way ANOVA with post hoc analysis, we determined that there
are no significant differences in fl-mhtt expression levels
between the SA, SD-B, and SD-C mice, whereas all of these lines
express fl-mhtt-[97Q] protein at significantly higher levels than
the BACHD-L line but at lower levels than the BACHD line, sug-
gesting that the SA, SD-B, and SD-C mice express sufficient
levels of fl-mhtt-[97Q] to elicit a disease phenotype.
To assess whether the SD or SA mutations affect the subcel-
lular distribution and/or the steady-state level of fl-mhtt, we per-
formed a series of western blot analyses. First, subcellular frac-
tionation of cytosolic, nuclear, microsomal, and mitochondrial
fractions of the BACHD, SA, and SD-C mice at 2 months of
age (n = 3 per genotype) was performed and followed by western
analysis using the 1C2 antibody. At our level of detection in the
mouse brain extracts, we do not observe any major shifts of
the subcellular localization of fl-mhtt or its detectable fragments
in SD or SA mutant mice compared to BACHD mice (Figure S4).
Next, we sought to determine the steady-state levels of soluble
fl-mhtt protein during the aging process to assess whether there
is any notable shift in fl-mhtt protein levels or increase in the
production of soluble mhtt fragments over time. In each of the
three mutant HD mouse lines we have examined, the levels of
soluble fl-mhtt are comparable between 2 and 12 months
(Figure S5). Moreover, in SD and SA mice, we do not detect
any aberrant increase of soluble mhtt polyQ fragments at830 Neuron 64, 828–840, December 24, 2009 ª2009 Elsevier Inc.12 months, suggesting that age-dependent differences in the
abundance of soluble full-length and fragmented mhtt cannot
account for any phenotypic changes.
In summary, our biochemical analyses demonstrate that SA,
SD-B, and SD-C mice express fl-mhtt-[97Q] at levels well above
the range expected to elicit disease pathogenesis in vivo.
Furthermore, we cannot detect marked differences in S13 and
S16 modified fl-mhtt and its polyQ fragments in their subcellular
localization or their steady-state, soluble levels over time.
Full-Length Mutant Huntingtin with S13 and S16
Mutations Preserves Normal Htt Function during
Development and in Adult Cortical Neurons
We next asked whether S13 and S16 mutated fl-mhtt could still
exhibit the essential functions of htt in vivo. We evaluated
whether cis-modified htt can rescue the phenotypes of htt
knockout mice, including embryonic lethality in the complete
null mutant mice (Zeitlin et al., 1995; White et al., 1997) and
late-onset cortical neuron degeneration in the forebrain-specific
deletion of the htt gene (Dragatsis et al., 2000). We previously
demonstrated that fl-mhtt-[97Q] in BACHD mice can rescue
the embryonic lethality of htt knockout mice, confirming that
fl-mhtt retains the essential developmental function of htt (Gray
et al., 2008). To assess whether fl-mhtt-[97Q] with SD or SA
mutations retain the function of htt, we crossed SA, SD-B, and
SD-C heterozygous alleles onto the htt knockout background
and scored for the number of the rescued mice born (Gray
et al., 2008). In all three lines, the rescued mice were born in










2 mo 6 mo 12 mo 12 mo 12 mo 12 mo 12 mo
BACHD 97 100% + + + + + + +
BACHD-L 97 32% + + n.d. n.d n.d. n.d +
SA 97 70% + + + + + + +
SD-B 97 54% - - - - - - -
SD-C 97 57% - - - - - - -
SD-C (het) 97 23% - - - - - - -
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seven rescued mice per genotype, and these rescued mice
express only fl-mhtt-[97Q] with S13 and S16 mutations, but not
endogenous wild-type murine htt (Figures 2B and 2C). Since
these rescued mice do not show obvious deterioration with
age, we could assess whether S13 and S16 mutated fl-mhtt
could also rescue the robust late-onset cortical neurodegenera-
tion phenotype between 6 and 12 months of age in the forebrain-
specific htt knockout mice (Dragatsis et al., 2000). We performed
neuropathological evaluation of the brain sections from
12-month-old SD-B rescue mice and WT control littermates
(n = 3 per genotype). As shown in Figures 2D–2G, we did not
detect any evidence for neurodegeneration in the cortex of
SD-B rescue mice (Figures 2F and 2G), including the piriform
cortex near the external capsule where the conditional knockout
of htt produced the most notable neurodegeneration (ibid).
Together, these studies demonstrate that fl-mhtt with SD or SA
mutations retains the essential developmental and neuroprotec-
tive function of murine htt.
Phosphomimetic Mutations at S13 and S16 Abolish
Motor and Psychiatric-like Deficits Induced by the
Expression of Full-Length Mutant Huntingtin
BACHD mice exhibit both motor deficits and enhanced psychi-
atric-like deficits (Gray et al., 2008; Menalled et al., 2009), which
can be used to address whether S13 and S16 site mutations
affect the neuronal dysfunction elicited by fl-mhtt in vivo. To
assess motor dysfunction, we applied a two-way mixed factorial
design to repeatedly examine the rotarod performance in
a cohort of SA, SD-B, and SD-C mice at 2, 6, and 12 months
of age. Similar to BACHD and BACHD-L mice (Gray et al.,
2008; Table 1), we found that SA mice also exhibit significant ro-
tarod deficits starting at 2 months of age (p < 0.0001, indepen-
dent sample Student’s t test), which progressively worsen at
6 and 12 months of age (p = 0.0001 for 6 month age, p <
0.0001 for 12 month age, Figure 3A). Repeated-measure two-
way ANOVA further revealed a significant genotype effect
(F(1,30) = 29.301, p < 0.0001). There is also a significant interac-
tion between genotype and age (F(1,30) = 4.965, p = 0.034). To
further evaluate effects of age on motor performance within
each genotype, we used one-way ANOVA to analyze the age
contribution to rotarod performance in separate genotypes.
We did not find any significant overall age effect in wild-type
mice (F(2,45) = 0.089, p = 0.915), but did find a significant maineffect of age in SA mice, (F(2, 45) = 3.390, p = 0.043), which
suggests a progressive impairment of rotarod performance.
Contrary to the findings in SA mice, two independent lines of
SD mice (SD-C and SD-B homozygotes) did not exhibit any
rotarod deficits compared to their respective WT littermate
controls at 2, 6, and 12 months (Figures 3B and 3C).
Repeated-measure two-way ANOVA did not detect a significant
genotype effect (for SD-B: F(1, 17) = 0.695, p = 0.416; for SD-C:
F(1,22) = 0.373, p = 0.548). Moreover, there is no significant inter-
action between genotype and age (for SD-B: F(1, 17) = 1.345,
p = 0.262; for SD-C: F(1, 22) = 0.006, p = 0.938).
We then compared rotarod performance of SD and SA mice to
the BACHD-L line. BACHD-L mice have significant rotarod
impairment at 6 months of age (Figure 3D). We also compared
the 6-month rotarod performance of the WT control mice from
different HD mouse lines using one-way ANOVA analysis and
found no significant differences among the four groups’ WT
controls (F(3, 38) = 1.292, p = 0.285 and p > 0.05 in pairwise
comparisons, Figure S6). Thus, rotarod performance changes
in these lines cannot be attributed to any differences in the WT
controls. We then compared the pooled WT controls with
SD-B and SD-C mice in their 6-month rotarod performance
(Figure 3D), which did not reveal any significant differences
between the genotypes (WT = 42, SD-B = 10, SD-C = 12, one-
way ANOVA with Fisher’s LSD post hoc test, p > 0.05). On the
other hand, both BACHD-L mice and the SA mice exhibited
significant motor impairment compared to WT, SD-B and
SD-C mice (BACHD-L = 12, SA = 8, one-way ANOVA with
Fisher’s LSD post hoc test, BACHD-L versus SD-B, p = 0.032;
BACHD-L versus SD-C, p = 0.025; SA versus SD-B,
p < 0.0001; SA versus SD-C, p < 0.0001; SA versus BACHD-L,
p = 0.029). Together, these studies demonstrate that SA muta-
tions still retain the toxicity of fl-mhtt and can elicit motor deficits,
while SD mutations abolish this disease phenotype in the
BACHD model system.
Although psychiatric symptoms are particularly difficult to
model in animals, several tests have been developed to assess
psychiatric-like behaviors that have at least some predictive val-
idity in patients (Crawley, 2008). BACHD mice were found to
exhibit a higher level of anxiety as measured by two different
tasks, the light-dark box and elevated plus maze (Menalled
et al., 2009). To assess whether SD or SA mutations in fl-mhtt
can modulate these anxiety-like behavioral deficits, we tested
12-month-old SD-B, SD-C, and SA mice and their respectiveNeuron 64, 828–840, December 24, 2009 ª2009 Elsevier Inc. 831
Figure 2. Mutant Huntingtin with S13 and S16 Mutations Preserve Normal Htt Function during Development and in Adult Cortical Neurons
(A) Heterozygous SD-B, SD-C, and SA transgenes were bred in two successive generations with murine Hdh heterozygous knockout mice (Zeitlin et al., 1995) to
generate the rescue mice (i.e., fl-mhtt transgene rescue the embryonic lethality of htt null mice). Since the homozygous Hdh null mice are embryonic lethal (ibid),
the expected ratio of rescue mice among the live mice born is 1 out of 7. The rescue mice for SD-B, SD-C, and SA were born with such Mendelian ratio.
(B and C) Western blot analyses with mAb2166 (Htt) and 1C2 to confirm that the rescue mice only express fl-mhtt and lack endogenous murine htt.
(D–G) SD fl-mhtt retains the essential adult neuronal function of htt in vivo. Nissl-stained coronal brain sections of 12-month-old SD-B rescue mice (F and G) and
WT littermates (D and E) at two different magnifications. No evidence of late-onset cortical neurodegeneration, as previously reported in the forebrain-specific htt
null mice (Dragatsis et al., 2000), was detected in these rescue mice.
Scale bars: (F) 500 mm, (G) 50 mm.
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anxiety phenotype compared to the controls (p = 0.0002, inde-
pendent sample Student’s t test), while the SD-B and SD-C
mice no longer exhibit the anxiety-like behavior compared to
their respective controls (SD-B versus WT p = 0.8991; SD-C
versus WT, p = 0.7606, independent sample Student’s t test;
Figure 3E). Thus, consistent with the motor test, the SD but not
SA mutations also appear to abolish the psychiatric-like behav-
ioral deficit observed in BACHD mice.
Full-Length Huntingtin with Phosphomimetic S13
and S16 Mutations Can Prevent the Onset
of Neurodegenerative Pathology In Vivo
BACHD brains at 12 months of age recapitulate aspects of selec-
tive neurodegenerative pathology in HD, particularly the selective
atrophy of the cortex and striatum with relative preservation of the
cerebellum (Gray et al., 2008). We next addressed whether the SA
and SD mutations in fl-mhtt could differentially impact the patho-
genesis of selective neurodegeneration in vivo. Similar to BACHD
mice, significant forebrain weight loss was detected in SA mice
compared to their WT littermate controls (Figure 4A, p =
0.0064, Student’s t test). However, both SD-B and SD-C mice
do not exhibit the forebrain atrophy phenotype compared to their
respective WT controls (SD-B versus WT, p = 0.1975; and SD-C832 Neuron 64, 828–840, December 24, 2009 ª2009 Elsevier Inc.versus WT, p = 0.7155, Student’s t test). In all three genotypes, no
significant cerebellar atrophy was detected (Figure 4B).
To more quantitatively evaluate both the cortical and striatal
atrophy in SA and SD mice, we applied the unbiased stereology
method to measure both the cortical and striatal volumes in 12-
month-old SA and SD-B mice. Similar to the BACHD mice (Gray
et al., 2008), we found that SA mice exhibit 17% reduction of
both the striatal and cortical volumes compared with their
WT littermates (Figures 4C and 4D; number of mice: WT = 4,
SA = 5; striatal volume: WT = 15.97 ± 0.8301 mm3; SA =
13.25 ± 0.6435 mm3; p = 0.0336, Student’s t test; cortical
volume: WT = 50.91 ± 1.332 mm3; SA = 42.49 ± 1.318 mm3;
p = 0.003, Student’s t test). On the contrary, SD-B mice do not
exhibit any striatal or cortical volume loss compared to their
WT controls (number of mice: WT = 4; SD-B = 5; striatal volume:
WT = 16.00 ± 0.5836 mm3; SD-B = 16.13 ± 0.4873 mm3;
p = 0.8635, Student’s t test; cortical volume: WT = 50.88 ±
0.7701 mm3; SD-B = 50.67 ± 1.357 mm3; p = 0.9025, Student’s
t test; Figures 4C and 4D).
Together, these data reveal that the SA and SD mutations have
opposing effects on the neurodegeneration phenotypes elicited
by fl-mhtt, with the SA fl-mhtt remaining neuropathogenic
whereas the SD fl-mhtt no longer induce the selective neurode-
generative pathology in vivo.
Figure 3. The SA but Not the SD Mice Demonstrate Motor and Psychiatric-like Behavioral Deficits
A mixed model two-way ANOVA design was used to examine the rotarod performance in a cohort of SA, SD-B, and SD-C mice at 2, 6, and 12 months of age.
(A) SA mice exhibit significant rotarod deficits starting at 2 months of age and persisting at 6 and 12 month ages (*p < 0.0001, Student’s t test).
(B and C) Two independent lines of SD mice (SD-C and SD-B homozygotes) did not exhibit any rotarod deficits compared to their respective WT littermate
controls at 2, 6, and 12 months.
(D) Comparison of 6-month-old BACHD-L, SA, SD-B, and SD-C lines rotarod performance. SD-B and SD-C mice did not show any significant impairment in their
6 month rotarod performance compared to wild-type controls. On the other hand, both BACHD-L mice and SA mice exhibited significant impairment compared to
WT, SD-B, and SD-C mice (one-way ANOVA with Fisher’s LSD post hoc test, p < 0.05; for details, see main text).
(E) The SA mice (p = 0.0002, Student’s t test) but not SD mice demonstrate significantly enhanced anxiety in light/dark box exploration test.
Error bars indicate mean ± SEM.
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Accumulation of Mutant Huntingtin Aggregates In Vivo
The ability of mhtt N-terminal fragments to form cytoplasmic
aggregates and nuclear inclusions was first discovered in a HD
mouse model (Davies et al., 1997), and such aggregates are
seen in BACHD mice (Gray et al., 2008). We tested whether the
monoclonal antibody 4H7H7 could detect mhtt aggregates con-
taining the expanded polyQ fragments in situ. Using antigen
retrieval followed by immunohistochemistry (Osmand et al.,
2006), 4H7H7 can selectively detect at least a subset of mhtt
aggregates in the HD patient cortices, but not age-matched
control cortices (Figure S7; see Supplemental Results). More-
over, we showed that the same 4H7H7 immunostaining proce-
dure allows for sensitive detection of mhtt neuropil and nuclear
aggregates in the cortex and striatum of four different HD mouse
models (Figure S8) (Davies et al., 1997; Gu et al., 2005; Slow
et al., 2003; Menalled et al., 2003).
In BACHD mice at 12 months of age, the 4H7H7 antibody can
readily detect mhtt aggregates in cortical and striatal sections
following the antigen-retrieval protocol, while the WT controls
do not have such staining (Figure 5). We can readily detect
mhtt aggregates in the cortex and striatum of 12-month-old SAmice, albeit at a somewhat lower level than in BACHD mice,
consistent with the lower expression of fl-mhtt in SA mice
compared to BACHD (Figure 5). The formation of these aggre-
gates in SA mice appears to be progressive, as they were not
detected at 2 months of age, and only sparsely detected at
6 months (Figure S9; data not shown). These results are consis-
tent with the progressive accumulation of mhtt aggregation in the
brains of HD mice and HD patients (Bates, 2003). Interestingly,
we did not detect 4H7H7-immunoreactive mhtt aggregates in
brain sections from 12-month-old SD mice (SD-B and SD-C)
(Figure 5).
Taken together, the in vivo results suggest that the SD muta-
tion prevents the onset of behavioral deficits and neuropa-
thology normally arising from polyQ repeat expansion in the
context of full-length human mhtt in HD mice, including motor
and psychiatric-like behavioral deficits, selective neurodegener-
ative pathology, and mhtt aggregation.
Phosphomimetic mHtt Exon1 Peptides Retard
Aggregation In Vitro
Since the SD or SA mutations appear to have differential effects on
disease pathogenesis, we hypothesize that they may conferNeuron 64, 828–840, December 24, 2009 ª2009 Elsevier Inc. 833
Figure 4. The SA but Not the SD Mice Elicit
Selective Neurodegeneration at 12 Month
Age
(A) Significant forebrain weight loss was detected
in 12-month-old SA mice compared to their WT
littermate controls (p = 0.0064, Student’s t test)
but not in SD-B or SD-C mice compared to their
respective controls.
(B) In all three genotypes, SA, SD-B, and SD-C,
no significant cerebellar atrophy was detected
(p > 0.05, Student’s t test).
(C) Unbiased stereology reveals significant
cortical volume loss in SA mice compared with
WT littermates (p = 0.0030, Student’s t test) but
not SD-B mice (p = 0.9025, Student’s t test).
(D) Unbiased stereology reveals significant striatal
volume loss in SA mice compared with their WT
littermates (p = 0.0336, Student’s t test). SD-B
mice do not exhibit significant striatal volume
loss compared to their WT controls (p = 0.8635,
Student’s t test).
Error bars indicate mean ± SEM.
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and/or aggregation properties of mhtt. In an in vitro study of htt
exon-1-related peptides, the NT17 sequence engages in a
reciprocal crosstalk with expanded polyQ sequences to radically
alter the aggregation pathway while greatly enhancing aggrega-
tion rate and producing an array of prefibrillar intermediates and
mature amyloid fibrils (Thakur et al., 2009). In this study, reduction
of net hydrophobicity via multiple mutations within NT17 clearly
suppressed the aggregation rate (Thakur et al., 2009). Based on
this result, we expected that the SA mutation (increased hydro-
phobicity) in NT17 mightenhance aggregation, while the SDmuta-
tion (decreased hydrophobicity) might decrease aggregation.
We used synthetic exon-1 peptides containing the WT, SD,
and SA NT17 domains to test these predictions. For synthetic
feasibility and convenience in the kinetics, we studied peptides
containing a Q37 repeat, a polyQ length at the threshold for
HD disease risk. Using an HPLC sedimentation assay, we found
that the SA double mutant of the exon-1 peptide aggregates
more rapidly than the same peptide with the WT NT17 sequence,
while the SD double mutant peptide aggregates more slowly
(Figure 6A; p < 0.005 for both, Student’s t test). More qualitative
differences are seen when the aggregation products are
analyzed by electron microscopy (EM). We harvested aggre-
gates at 96 hr, when aggregation was essentially complete.
The aggregates of the SA double mutant exon-1 peptide
(Figure 6C) are morphologically indistinguishable from the aggre-
gates of the WT peptide (Figure 6B), both being highly homoge-
neous preparations of long, straight, relatively thick fibrils. In
contrast, the aggregates from the SD double mutant exon-1
peptide are quite heterogeneous, consisting of an assortment
of short, protofibril-like aggregates and bundles of very thin fila-
ments (Figures 6D–6H). Based on the EM data, the SD aggre-
gates appear to be a mixture of stabilized exon-1 aggregation
intermediates, and products of an alternative aggregation834 Neuron 64, 828–840, December 24, 2009 ª2009 Elsevier Inc.pathway (A.K. Thakur, M. Jayaraman, R. Kodali, R. Mishra, and
R. Wetzel, unpublished data).
We next asked whether a single phosphomimetic mutation at
S13 or S16 can recapitulate the effects of SD double mutations
on mhtt exon-1 peptide aggregation. Interestingly, the S16D
single mutant can mimic the reduced aggregation rate of the
SD double mutant in the HPLC sedimentation assay, while the
S13D mutant aggregates at a comparable rate to the WT peptide
(Figure S10). However, when we examined the morphologies of
the completed aggregation product at 96 hr, both S13D and
S16D single mutant peptides resulted in mixtures of mature
amyloid fibrils similar to those from WT NT17 and short protofi-
bril-like aggregates similar to those from SD double mutants
(Figure S10). Since the SD double mutant exhibits negligible
mature fibrils, it appears that both the S13D and S16D mutations
contribute, in a cumulative fashion, to altering the exon-1 aggre-
gation pathway.
While more work is required to understand the mechanism of
the SD mutations’ effects on the aggregation, structure, and
physical properties of the htt aggregation products, our in vitro
results suggest that SD mutations somehow modulate the mis-
folding and aggregation of mhtt fragment induced by polyQ
expansion. The SD mutations appear to act by either redirecting
aggregation down a different assembly pathway or by retarding
the normal assembly pathway, in either case resulting in reduced
aggregation kinetics and altered aggregate morphologies.
DISCUSSION
Our study provides direct in vivo mammalian genetic evidence to
support a critical role for htt S13 and S16 residues in preventing
fl-mhtt-induced disease pathogenesis in HD mouse models.
Both phosphomimetic mutations (SD) and phosphoresistant
mutations (SA) can rescue phenotypes of htt null mice. The
Figure 5. SD Mutations but Not SA Mutations Prevent the Accumulation of mhtt polyQ Aggregate in the Brain
Mutant huntingtin aggregates in HD patient brains and existing HD mouse brains can be readily detected by immunostaining with 4H7H7, a monoclonal antibody
that selectively recognizes the expanded polyQ epitope (see Figures S3, S6, and S7 and Supplemental Results). Using the same antibody, we can readily detect
mhtt aggregates accumulated in the cortical layers 2–3, layers 5–6, and striata of 12-month-old BACHD and SA mice but not WT littermate controls brains. Such
stainings are absent in the 2-month-old SA mice (Figure S8). However, in the 12-month-old SD-B and SD-C brains, 4H7H7-stained mhtt aggregates are absent in
all brain regions, including cortical layers 2–3, layers 5–6, and striata.
Scale bar, 50 mm.
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tions in the context of fl-mhtt can prevent behavioral deficits,
selective neurodegeneration, and accumulation of mhtt aggre-
gates in the BAC transgenic mouse models of HD (Table 1).
In vitro kinetic studies with purified mhtt exon-1 peptides reveal
that modifications of serines 13 and 16 alter the course and
kinetics of aggregation, with SD reducing fibrillization while
accumulating alternative aggregate products, and SA maintain-
ing the normal aggregation patterns of the expanded repeatlength (Thakur et al., 2009). These results suggest that modifica-
tion of the two serine residues is capable of altering the structural
properties of this domain. Taken together, the results demon-
strate that subtle molecular changes of only two amino acids in
the NT17 domain in the context of the large full-length human
mutant htt protein can dramatically reduce the pathogenic
potential of the mutant protein in vivo. Hence, our results provide
strong support for the hypothesis that S13 and S16 in the htt
NT17 domain may act as a molecular switch to regulate diseaseNeuron 64, 828–840, December 24, 2009 ª2009 Elsevier Inc. 835
Figure 6. In Vitro Aggregation of Exon-1
Peptides and a Schematic Model on Serines
13 and 16 as a Critical Molecular Switch of
HD Pathogenesis
(A) HPLC-based sedimentation assays indicate
differences in the aggregation of WT:10.8 mM (d,
R2 = 0.9832, SE = 6.7), SA:10.9 mM (A, R2 =
0.9843, SE = 6.3), and SD:10 mM (:, R2 =
0.9863, SE = 3.2) NT17Q37P10K2 peptides. The
experiments were done in duplicate (for WT) and
triplicate (SA and SD mutants), and the data
were fit using Sigma Plot 10.0 software to
a single-exponential three-parameter decay func-
tion. Error bars indicate mean ± SEM.
(B–H) Electron microscope images on aggregates
harvested after 96 hr aggregation time. WT (B) and
SA mutant (C) peptide aggregates are morpholog-
ically equivalent. SD mutant peptide aggregates
(D–H) include none of these mature amyloids but
rather are composed of a mixture of alternative
morphologies associated with aborted and/or
alternative aggregation pathways.
(I) A schematic model of how serines 13 and 16 act
as a molecular switch to dichotomize fl-mhtt-
induced disease pathogenesis. Depending on
the molecular state of S13 and S16, fl-mhtt may
be involved in two distinct molecular pathways.
In the toxic mhtt pathway, when S13 and S16 are
not phosphorylated, a state mimicked by SA
mutations, fl-mhtt may mediate its toxicity via
interaction with yet undefined protein X, or it may
be cleaved into toxic mhtt polyQ fragments that
may misfold and form toxic monomers, oligomers,
aggregates, and mature amyloid fibrils. Moreover,
these mhtt species may be difficult to be cleared
by the lysosome or proteosome (Thompson
et al., 2009). Overall, the unphosphorylated or SA
form of fl-mhtt can elicit HD pathogenesis
in vivo. In contrast, phosphorylation of S13 and
S16, modeled by SD mutations, may induce
biophysical changes to alter its polyQ-induced
protein misfolding and/or protein-protein interac-
tions (e.g., interacting with protein Y instead of
protein X) and slow the kinetics of htt aggregation
and impair the formation of mature amyloid fibrils,
thereby enhancing the clearance of mhtt species.
Overall, our study provides the proof-of-principle
that molecular targeting of S13 and S16 (i.e., SD
mutations) may convert fl-mhtt into a functional
but nontoxic form in vivo and hence represents
an attractive novel target for HD therapy.
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molecular pathogenic mechanism may have a dramatic thera-
peutic impact.
Significance of S13 and S16 Residues in HD
Pathogenesis In Vivo
A critical challenge in HD research is to identify which subset of
molecular mechanisms could have a significant role in deter-
mining disease pathogenesis and in developing therapeutics836 Neuron 64, 828–840, December 24, 2009 ª2009 Elsevier Inc.(Orr and Zoghbi, 2007; Beal and Ferrante, 2004; Li and Li,
2006). One fruitful approach to study polyQ disease pathogen-
esis is to assess how the distinct protein context of the polyQ
repeat (i.e., other domains or covalent modifications) may be
involved in controlling disease pathogenesis (Orr and Zoghbi,
2007). In HD, multiple htt protein domains and covalent htt modi-
fications have been implicated in disease pathogenesis (e.g.,
Steffan et al., 2004; Duennwald et al., 2006; Jeong et al.,
2009). However, only the caspase cleavage sites have been
Neuron
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fl-mhtt in transgenic mice (Graham et al., 2006). The in vivo
significance of the modification of S13 and S16 in the context
of fl-mhtt-induced disease pathogenesis in a mammalian model
of HD is directly addressed by this study.
An important goal in studying HD pathogenesis is to identify
critical molecular pathogenic mechanisms that can prevent the
early-onset neuronal dysfunction and late-onset neurodegener-
ation induced by mhtt (Gusella and MacDonald, 2000). Our study
clearly demonstrates that the S13 and S16 sites may act as
a molecular switch to prevent these pathogenic events. We
determined that SD mice do not display early neuronal dysfunc-
tion as demonstrated by motor and psychiatric-like behavioral
deficits, which are readily detectable in mice with SA mutations
or with unmodified fl-mhtt (Gray et al., 2008; Menalled et al.,
2009). In addition, we were able to demonstrate that SD, but
not SA mutants can rescue late-onset neurodegeneration as as-
sayed by selective forebrain weight loss and cortical and striatal
atrophy. Our study suggests that NT17 domain and its modifica-
tions are critical regulators of very early pathogenic events that
initiate the cascade of downstream pathogenic events.
S13 and S16 Modification May Regulate Mutant
Huntingtin Misfolding and Aggregation
Protein misfolding leading to amyloid fibril formation is a widely
investigated molecular pathogenic mechanism for a large group
of age-dependent neurodegenerative disorders (Ross and
Poirier, 2004; Williams and Paulson, 2008; Bossy-Wetzel et al.,
2004). A key mechanistic finding of this study is the effect of
S13 and S16 mutations on mhtt misfolding and aggregation.
Accumulation of nuclear and cytoplasmic aggregates is a patho-
logical hallmark of HD (DiFiglia et al., 1997; Gutekunst et al.,
1999). Prior studies have demonstrated that mutations in the
NT17 domain may affect the aggregation and/or nuclear accu-
mulation of mhtt N-terminal fragments in transfected cells (Rock-
abrand et al., 2007; Atwal et al., 2007). We have found that modi-
fication of the NT17 Ser residues can dramatically alter the
course of aggregation. In particular, the SD double mutant slows
the aggregation rate and prevents the normal course of the
aggregation reaction. In contrast, the SA double mutant aggre-
gates more rapidly than the WT NT17 peptide to generate prod-
ucts with morphology indistinguishable from that of the WT.
Moreover, the single S13D or S16D mutants appear to offer
partial protection against formation of mature amyloid fibrils, sug-
gesting that a cumulative effect of Ser to Asp mutations underlies
the ability of the SD double mutant to counteract the propensities
of mhtt exon-1 peptides for misfolding and aggregation in vitro.
These results are consistent with previous in vitro results showing
that mutations within the NT17 domain that reduce hydropho-
bicity reduce aggregation rates (Thakur et al., 2009).
Importantly, the aggregation behavior of these exon-1 model
peptides correlates well with the differential mhtt aggregate
accumulation in the SD and SA brains in vivo, suggesting that
the SD mutations may also have a significant impact on the
structure and physical properties of fl-mhtt or its fragments
in vivo. We have found that 12-month-old SA mutants, which
have phenotypes similar to BACHD mice, exhibit mhtt aggregates
in the cortex and striatum, while 12-month-old SD mutants exhibitno detectible aggregates (Figure 5). Consistent with the in vitro
aggregation results (Figure 6), the lack of detectible aggregates
in the SD mice may be due to a slow and incomplete aggregation
process or prolonged lifetimes of aggregation intermediates.
These aggregation intermediates might be less readily detected
by the 4H7H7 antibody or may be more easily cleared in affected
neurons compared to mature amyloid fibrils from SA and WT
mhtt. The latter possibility is supported by the findings that
SD but not SA mutations in the context of mhtt exon-1 frag-
ments or fl-mhtt can enhance its clearance via lysosome or pro-
teosome in cultured mammalian cells (Thompson et al., 2009).
In summary, our study provides convergent in vitro and in vivo
evidence that SD but not SA mutations alter the biophysical
properties of NT17 domain, counteracting the molecular conse-
quences of mhtt polyQ expansion such as protein misfolding
and aggregation.
Molecular Pathways Implicated in S13 and S16
Phosphorylation in Huntingtin
Our study suggests that the phosphorylation status of the two
serine residues in the NT17 domain can influence the pathogenic
consequences of expression of fl-mhtt protein in the mammalian
brain (Figure 6I). This is consistent with the converging evidence
supporting the important role of NT17 domain and its modifica-
tions in mhtt-induced neuronal toxicity in cellular and inverte-
brate models of HD (Steffan et al., 2004; Rockabrand et al.,
2007; Atwal et al., 2007; Subramaniam et al., 2009; Thompson
et al., 2009). Our result highlights the importance of elucidating
the molecular pathways, particularly the kinases and phospha-
tases, which modulate these phosphorylation events in the HD
brain. Also, it will be important to uncover the downstream
molecular cascades resulting from S13 and S16 phosphorylation
that mediate the suppression of fl-mhtt-induced disease patho-
genesis (Figure 6I).
Currently, very little is known about the potential partners that
can interact with htt via the NT17 domain. However, two recent
studies may shed some light onto this issue. In both a yeast
and mammalian cell line model (Omi et al., 2008; Wang et al.,
2009), the htt NT17 domain is shown to bind to 14-3-3 proteins,
which are known to bind to phosphorylated proteins. Since the
NT17 domain has two serine and one threonine residue, we
speculate that 14-3-3 proteins may be able to bind to S13 or
S16 upon its phosphorylation and such binding may modulate
mhtt toxicity in vivo. This hypothetical model for HD is reminis-
cent of SCA1 pathogenesis in which 14-3-3 proteins can modu-
late polyQ expanded ataxin-1 mediated disease via binding to
phosphorylated serine 776 (Chen et al., 2003). Thus, future
molecular studies should focus on establishing the signaling
pathways that lead to alteration of htt S13 and S16 phosphoryla-
tion and in identifying phosphorylation-dependent protein-
protein interaction that may be responsible for the suppression
of fl-mhtt toxicities in vivo.
Therapeutic Implications of Huntingtin S13 and S16
Phosphorylation
Our study suggests that targeting the mhtt NT17 domain may be
therapeutic for HD, particularly prior to the onset of disease.
Consistent with this, a single-chain Fv intrabody against httNeuron 64, 828–840, December 24, 2009 ª2009 Elsevier Inc. 837
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terminal fragments in vivo (Wolfgang et al., 2005; Southwell et al.,
2008). Another important finding of our study is that S13 and S16
phosphomimetic mutations do not elicit disease pathogenesis
but do maintain normal htt function in embryonic development
and the adult brain (Figures 2 and 6I). This result suggests an
exciting therapeutic possibility of converting a toxic form of fl-
mhtt into a functional but nontoxic form. Molecular analyses of
the differences between SD mhtt and other forms of mhtt may
help to design high-throughput screening assays for identifica-
tion of compounds that modify fl-mhtt elicited disease patho-
genesis.
In conclusion, we have demonstrated the significance of S13
and S16 residues in disease pathogenesis elicited by HD trans-
genic mouse models. Our findings suggest that specific S13 and
S16 modifications in fl-mhtt may act as a molecular switch to
suppress HD pathogenesis in the mammalian brain, thus
providing an important avenue for the development of new ther-
apeutics for this currently incurable neurodegenerative brain
disorder.
EXPERIMENTAL PROCEDURES
Generation of BAC Transgenic Mice
We used site-directed mutagenesis to modify the shuttle vector plasmid,
pLD53-SCAB-HDexon1-97Q (Gray et al., 2008). Serines 13 and 16 were
mutated to either aspartic acid (SD) or alanine (SA) using QuikChange Multi
Site-Directed Mutagenesis Kit (Stratagene). The following oligonucleotide
primers were used to introduce the SD mutation (50-AAG CTG ATG AAG
GCC TTC GAG GAC CTC AAA GAC TTC CAA CAG CAG CAA CAG CAA C-
30 ) or SA mutation (50-AAG CTG ATG AAG GCC TTC GAG GCC CTC AAA
GCC TTC CAA CAG CAG CAA CAG CAA C-30). PCR products from mutagen-
esis reactions were used to transfect Pir2 competent cells (Invitrogen). Correct
RecA-based shuttle vector plasmids were used to engineer a human htt BAC
(Gray et al., 2008) to introduce the SD and SA mutations (Yang et al., 1997;
Gong et al., 2002; Yang and Gong, 2005). The final modified BAC were
confirmed by DNA sequencing to contain the SD or SA mutations and to
have 97 mixed CAA-CAG codons encoding the expanded polyQ repeat (see
Supplemental Experimental Procedures). The modified BAC DNA was
prepared according to our published protocols and microinjected into FvB
fertilized oocytes at the UCLA Transgenic Core. BACHD, BACHD-L, SD, and
SA mice were maintained in the FvB/NJ background and bred and maintained
under standard conditions consistent with National Institutes of Health
guidelines and approved by the UCLA Institutional Animal Care and Use
Committees.
Preparation of Brain Extracts and Western Blotting
We used our published protocols for the preparation of brain protein extracts
and western blot analyses (Gray et al., 2008; see Supplemental Experimental
Procedures). Immunoblots were probed with anti-Htt 2166 (Abcam, mAb2166,
1:3000), 1C2 (Millipore, MAB1574, 1:3000), S13-P, and S16-P phosphor-
specific antibodies (1:1000; Thompson et al., 2009), and a-tubulin (Sigma,
1:10,000).
Genetic Rescue of Murine Huntingtin Null Phenotypes by SD and SA
BAC Transgenes
The genetic rescue of murine htt knockout phenotypes during embryonic
development is similar to our published study (Gray et al., 2008). Briefly,
heterozygous BACHD-SD and BACHD-SA transgene alleles were bred with
murine Hdh heterozygous mice (Zeitlin et al., 1995) to generate double hetero-
zygous mice. These double heterozygous mice were then crossed to Hdh
heterozygotes to create homozygous Hdh mice either with or without the
BAC transgenes, and the number of mice with these genotypes were scored838 Neuron 64, 828–840, December 24, 2009 ª2009 Elsevier Inc.among the offspring born. The rescue mice were defined as mice without
two endogenous Hdh alleles but with the heterozygous BACHD-SD or
BACHD-SA transgenes. No mice with both Hdh null alleles but without any
BACHD-SD or SA transgenes were among the live littermates in our study (Zei-
tlin et al., 1995).
To assess the ability of BACHD-SD transgene in rescuing the adult neurode-
generation phenotype ofHdh forebrain-specific knockout mice, three BACHD-
SD rescue mice and WT littermate controls were sacrificed at 12 months of
age. Coronal brain sections were prepared and used to examine for marked
cortical neurodegeneration as described before (Dragatsis et al., 2000).
Behavioral Tests of Mutant HD Mice
Mice were tested for motor impairment using our established rotarod test
(Gray et al., 2008). We tested the following group of mice at 2, 6, and 12
months: SA mice (WT = 12, Tg = 13), SD-B (WT = 10, Tg = 13), SD-C (WT =
10, Tg = 13), and BACHD-L (WT = 17; Tg = 20). For each genotype, we used
approximately equal number of males and females. The mice were trained
on an Ugo Basile 7650 accelerating rotarod (0 to 40 RPM in 5 min) for three
trials per day for 2 days at 2 months of age. The same cohort of mice was
tested for three trials per day for 3 consecutive days at 2, 6, and 12 months
of age. All rotarod tests were performed during the light phase of the light
cycle.
Anxiety-like behavior was assessed in the light/dark box exploration test
(File, 1997). The light/dark exploration box is made of plexiglass with a clear
(light) side (27 3 27 3 30 cm) and a smaller, fully opaque (dark) side (18 3
27 3 30 cm) separated by a partition with a small opening. The dark side is
completely closed to light. The lighted side is illuminated with a 60 W light
bulb or light with an illuminance of about 400 lux. Light/dark exploration was
performed during the early phase of the light/dark cycle. Mice were placed
in testing room at least 1 hr before testing. The mice are tested for 10 min in
the light/dark box and assessed for movements from one side to another.
The same cohort of SD and SA mice and respective wild-type controls from
the above rotarod tests were tested at 12 months of age in this light/dark
exploration test.
Antigen Retrieval and Immunohistochemical Staining of polyQ
Mutant Htt Aggregates with Monoclonal 4H7H7 Antibody
Mice were perfused transcardially with 4% paraformaldehyde in 0.1 M PBS.
After 6 hr post-fix at 4C, brains were cryoprotected with 30% sucrose in
0.1 M PBS at 4C, and frozen coronal brain sections (40 mm) were cut on a cryo-
stat. The antigen-retrieval procedure is described in more detail elsewhere
(Osmand et al., 2006). Briefly, the brain sections were antigen treated with for-
mic acid and followed by 1% sodium borohydride. Biotinylated monoclonal
antibody 4H7H7 was then used at a concentration of 50 ng/ml and incubated
with the brain sections overnight at 4C. Subsequently, the immunostaining
signal was amplified with Tyramide Signal Amplification kit (Perkin Elmer)
and detected with SD-AG chromogen (Vector Lab.).
Brain Weight and Stereological Brain Volume Measurements
The quantitative analyses of brain weights and stereological measurements of
cortical and striatal volumes using the optical fractionator method using Stereo
Investigator software (MicroBrightField) were identical to our published proto-
cols for BACHD mice (Gray et al., 2008).
Analysis of In Vitro Htt-exon 1 Peptide Aggregate Formation
Chemically synthesized peptides were obtained from the Keck Biotechnology
Center at the Yale University (http://keck.med.yale.edu/ssps/), purified by
reverse phase HPLC, and the purity determined and identities confirmed by
mass spectrometry using an Agilent 1100 Electrospray MSD. The structures
of the peptides used were NT17-Q37P10K2, in which the sequence of wild-
type NT17 is MATLEKLMKAFESLKSW and the underscored Ser residues
are the ones replaced by Ala or Asp in the SA, SD, and single S13D and
S16D mutants. Phe17 was replaced by Trp in these peptides to be used as
a fluorescent probe; we have observed no effects on aggregation or other
properties in Phe17/Trp mutants (Thakur et al., 2009). Purified peptides
were lyophilized and freshly disaggregated before use as described (O’Nual-
lain et al., 2006), then dissolved in phosphate-buffered saline and incubated
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measuring the amount of monomer remaining in solution at different times
using the sedimentation assay (O’Nuallain et al., 2006). Electron micrographs
of the aggregates were obtained by directly analyzing aliquots of the reaction
mixture collected at different times. For each determination, 5 ml of the sample
was placed on a freshly glow-discharged Formvar carbon-coated grid and ad-
sorbed for 2 min, after which the grid was washed with deionized water before
staining the protein with 2 ml of 1% (w/v) uranyl acetate and removing excess
stain by blotting. Grids were imaged on a Tecnai T12 microscope (FEI) oper-
ating at 120 kV and 30,0003 magnification and equipped with an UltraScan
1000 CCD camera (Gatan) with postcolumn magnification of 1.43.Statistical Analysis
Statistical analyses of the behavioral phenotypes and neuropathological phen-
toypes of BACHD-SD and SA mice and BACHD-L mice were similar to our
published protocols (Gray et al., 2008). All data are shown as the mean ± stan-
dard error of the mean (SEM). For rotarod analysis, SPSS 14.0 statistics soft-
ware (Chicago, IL) was used. The significance level was set at 0.05. A general
linear model ANOVA with repeated-measures was performed to assess the
main effects of age, genotype, and their interaction. In some data sets, one-
way ANOVA was used to analyze the time effect on rotarod performance of
BACHD mice and wild-type mice from 2, 6, and 12 months of age. Fisher’s
LSD post hoc analysis was performed for pairwise comparisons among
ages. For neuropathology and stereology studies, all comparisons between
BACHD and wild-type mice are shown as mean ± SEM. Comparisons were
made with an independent sample Student’s t test with a significance level
of 0.05. For electrophysiological studies, data in the text and figures are pre-
sented as mean ± SEM. Differences between groups were assessed with
Student’s t tests or appropriate designed ANOVAs. The significance level
was set at 0.05.SUPPLEMENTAL DATA
Supplemental Data include ten figures, Supplemental Results, and Supple-
mental Experimental Procedures and can be found with this article online at
http://www.cell.com/neuron/supplemental/S0896-6273(09)00936-2.ACKNOWLEDGMENTS
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